As one approach to distinguish this clinical dilemma, recently, MHC class I-associated tumor-specific phosphopeptides presented on hematological tumors were shown to be critical for induction of their specific memory-like CD8+T cells against leukemia and that the response against leukemic patients can be restored after allo-HCT (110). Here, CD8A is linked to neoplasm.